How do Sprycel and Gleevec compare head-to-head in CML?
Sprycel (dasatinib) and Gleevec (imatinib) are both tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia (CML). Gleevec was the first TKI, transforming CML from fatal to manageable since its 2001 approval. Sprycel, approved in 2006, followed as a second-generation option. Neither is universally "better"—choice depends on disease phase, patient response, and tolerance. Clinical trials show Sprycel often achieves deeper, faster responses in newly diagnosed patients but with higher toxicity risks.[1][2]
What do key clinical trials say about response rates?
In the DASISION trial, newly diagnosed chronic-phase CML patients on Sprycel (100 mg daily) had higher major molecular response (MMR) rates at 12 months (46% vs 28% for Gleevec 400 mg) and 24 months (64% vs 46%). Cumulative complete cytogenetic response was also superior (84% vs 72% at 24 months).[3]
The DIRECT trial echoed this: Sprycel reached MMR faster (84% vs 60% at 24 months).[4]
For frontline use, both achieve high 5-year overall survival (~90-95%), but Sprycel edges out in molecular milestones, potentially allowing more patients to stop therapy later.[1]
When is Sprycel preferred over Gleevec?
Sprycel excels in cases where Gleevec fails or resistance emerges (e.g., T315I mutation, where ponatinib might be better). Guidelines from NCCN and ELN recommend Sprycel as a frontline alternative, especially for faster responses or high-risk Sokal scores.[5] It's also approved for accelerated or blast-phase CML, where Gleevec underperforms. Real-world data shows ~20-30% of patients switch from Gleevec to Sprycel due to suboptimal response.[2]
What are the main side effect differences?
Gleevec causes more fluid retention, nausea, muscle cramps, and rash—often manageable with dose tweaks. Sprycel brings higher rates of pleural effusion (10-15% vs <1%), pulmonary hypertension, and myelosuppression (neutropenia in 40-50%). Both carry cardiovascular risks, but Sprycel's profile led to black-box warnings for pulmonary issues. Discontinuation due to adverse events is similar (~10-15% over 5 years).[1][3]
| Aspect | Gleevec (Imatinib) | Sprycel (Dasatinib) |
|--------|---------------------|---------------------|
| Common Side Effects | Edema, nausea, fatigue | Pleural effusion, diarrhea, headache |
| Serious Risks | Heart failure (rare) | Pulmonary hypertension, QT prolongation |
| Monitoring | Liver function, fluids | Lung imaging, CBC frequently |
Cost and access considerations
Gleevec generics (since 2016) make it cheaper (~$100-500/month). Sprycel generics launched in 2025 after patent expiry (U.S. Patent No. 6,596,746 expired 2024).[6] Brand Sprycel costs $10,000-15,000/month without insurance. Patient assistance programs exist for both.
What do long-term outcomes and guidelines show?
Five-year progression-free survival favors Sprycel slightly (93% vs 89% in DASISION), but differences narrow over time. ELN 2020 guidelines list both as frontline standards; Tasigna (nilotinib) competes similarly. For TFR (treatment-free remission), deeper responses with Sprycel help qualify more patients (~50% success rate).[5] No head-to-head mortality benefit exists.
Sources:
[1] NEJM: DASISION Trial (2010)
[2] Blood Journal Review (2011)
[3] NEJM DASISION Update (2012)
[4] Leukemia: DIRECT Trial (2016)
[5] NCCN CML Guidelines (v2.2024)
[6] DrugPatentWatch: Sprycel Patents